Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs GSK 3390107A (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Oct 2017 Status changed from active, no longer recruiting to completed.
- 31 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
- 31 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2017.